Study of 2 million patients maps benefits and risks of new weight-loss drugs
GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney problems.
Study of 2 million patients maps benefits and risks of new weight-loss drugs.(photo credit: MKPhoto12. Via Shutterstock)